Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma

Mei Zheng, Anamarija M. Perry, Philip Jay Bierman, Fausto Loberiza, Michel R. Nasr, David Szwajcer, Marc R. Del Bigio, Lynette M Smith, Weiwei Zhang, Timothy Charles Greiner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Primary CNS diffuse large B-cell lymphoma (PCNS-DLBCL) and systemic DLBCL harbor mutations in MYD88 and CD79B. DNA methyltransferase (MGMT) is methylated in some DLBCL. Our goal was to investigate the frequencies of these events, which have not been previously reported within the same series of patients with PCNS-DLBCL. Fifty-four cases of PCNS-DLBCL from two institutions were analyzed by Sanger sequencing for MYD88 and CD79B, and pyrosequencing for MGMT. MYD88 mutations were identified in 68.8% (35 of 51 cases), with L265P being the most frequent mutation. Mutations other than L265P were identified in 21.6% of cases, of which eight novel MYD88 mutations were identified. Of mutated cases, 17.6% had homozygous/hemizygous MYD88 mutations, which has not been previously reported in PCNS-DLBCL. CD79B mutations were found in six of 19 cases (31.6%), all in the Y196 mutation hotspot. MGMT methylation was observed in 37% (20 of 54 cases). There was no significant difference in median overall survival (OS) between the wild type and mutated MYD88 cases, or between methylated and unmethylated MGMT cases. However, a significant difference (P = 0.028) was noted in median OS between the wild type and mutated CD79B cases.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalNeuropathology
Volume37
Issue number6
DOIs
StatePublished - Dec 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Methylation
Central Nervous System
Mutation
Survival
Methyltransferases
DNA

Keywords

  • CD79B
  • Lymphoma
  • MGMT methylation
  • MYD88
  • central nervous system

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. / Zheng, Mei; Perry, Anamarija M.; Bierman, Philip Jay; Loberiza, Fausto; Nasr, Michel R.; Szwajcer, David; Del Bigio, Marc R.; Smith, Lynette M; Zhang, Weiwei; Greiner, Timothy Charles.

In: Neuropathology, Vol. 37, No. 6, 12.2017, p. 509-516.

Research output: Contribution to journalArticle

Zheng, Mei ; Perry, Anamarija M. ; Bierman, Philip Jay ; Loberiza, Fausto ; Nasr, Michel R. ; Szwajcer, David ; Del Bigio, Marc R. ; Smith, Lynette M ; Zhang, Weiwei ; Greiner, Timothy Charles. / Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. In: Neuropathology. 2017 ; Vol. 37, No. 6. pp. 509-516.
@article{8bff650b6bb746f6ac039cfbecabaa7c,
title = "Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma",
abstract = "Primary CNS diffuse large B-cell lymphoma (PCNS-DLBCL) and systemic DLBCL harbor mutations in MYD88 and CD79B. DNA methyltransferase (MGMT) is methylated in some DLBCL. Our goal was to investigate the frequencies of these events, which have not been previously reported within the same series of patients with PCNS-DLBCL. Fifty-four cases of PCNS-DLBCL from two institutions were analyzed by Sanger sequencing for MYD88 and CD79B, and pyrosequencing for MGMT. MYD88 mutations were identified in 68.8{\%} (35 of 51 cases), with L265P being the most frequent mutation. Mutations other than L265P were identified in 21.6{\%} of cases, of which eight novel MYD88 mutations were identified. Of mutated cases, 17.6{\%} had homozygous/hemizygous MYD88 mutations, which has not been previously reported in PCNS-DLBCL. CD79B mutations were found in six of 19 cases (31.6{\%}), all in the Y196 mutation hotspot. MGMT methylation was observed in 37{\%} (20 of 54 cases). There was no significant difference in median overall survival (OS) between the wild type and mutated MYD88 cases, or between methylated and unmethylated MGMT cases. However, a significant difference (P = 0.028) was noted in median OS between the wild type and mutated CD79B cases.",
keywords = "CD79B, Lymphoma, MGMT methylation, MYD88, central nervous system",
author = "Mei Zheng and Perry, {Anamarija M.} and Bierman, {Philip Jay} and Fausto Loberiza and Nasr, {Michel R.} and David Szwajcer and {Del Bigio}, {Marc R.} and Smith, {Lynette M} and Weiwei Zhang and Greiner, {Timothy Charles}",
year = "2017",
month = "12",
doi = "10.1111/neup.12405",
language = "English (US)",
volume = "37",
pages = "509--516",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma

AU - Zheng, Mei

AU - Perry, Anamarija M.

AU - Bierman, Philip Jay

AU - Loberiza, Fausto

AU - Nasr, Michel R.

AU - Szwajcer, David

AU - Del Bigio, Marc R.

AU - Smith, Lynette M

AU - Zhang, Weiwei

AU - Greiner, Timothy Charles

PY - 2017/12

Y1 - 2017/12

N2 - Primary CNS diffuse large B-cell lymphoma (PCNS-DLBCL) and systemic DLBCL harbor mutations in MYD88 and CD79B. DNA methyltransferase (MGMT) is methylated in some DLBCL. Our goal was to investigate the frequencies of these events, which have not been previously reported within the same series of patients with PCNS-DLBCL. Fifty-four cases of PCNS-DLBCL from two institutions were analyzed by Sanger sequencing for MYD88 and CD79B, and pyrosequencing for MGMT. MYD88 mutations were identified in 68.8% (35 of 51 cases), with L265P being the most frequent mutation. Mutations other than L265P were identified in 21.6% of cases, of which eight novel MYD88 mutations were identified. Of mutated cases, 17.6% had homozygous/hemizygous MYD88 mutations, which has not been previously reported in PCNS-DLBCL. CD79B mutations were found in six of 19 cases (31.6%), all in the Y196 mutation hotspot. MGMT methylation was observed in 37% (20 of 54 cases). There was no significant difference in median overall survival (OS) between the wild type and mutated MYD88 cases, or between methylated and unmethylated MGMT cases. However, a significant difference (P = 0.028) was noted in median OS between the wild type and mutated CD79B cases.

AB - Primary CNS diffuse large B-cell lymphoma (PCNS-DLBCL) and systemic DLBCL harbor mutations in MYD88 and CD79B. DNA methyltransferase (MGMT) is methylated in some DLBCL. Our goal was to investigate the frequencies of these events, which have not been previously reported within the same series of patients with PCNS-DLBCL. Fifty-four cases of PCNS-DLBCL from two institutions were analyzed by Sanger sequencing for MYD88 and CD79B, and pyrosequencing for MGMT. MYD88 mutations were identified in 68.8% (35 of 51 cases), with L265P being the most frequent mutation. Mutations other than L265P were identified in 21.6% of cases, of which eight novel MYD88 mutations were identified. Of mutated cases, 17.6% had homozygous/hemizygous MYD88 mutations, which has not been previously reported in PCNS-DLBCL. CD79B mutations were found in six of 19 cases (31.6%), all in the Y196 mutation hotspot. MGMT methylation was observed in 37% (20 of 54 cases). There was no significant difference in median overall survival (OS) between the wild type and mutated MYD88 cases, or between methylated and unmethylated MGMT cases. However, a significant difference (P = 0.028) was noted in median OS between the wild type and mutated CD79B cases.

KW - CD79B

KW - Lymphoma

KW - MGMT methylation

KW - MYD88

KW - central nervous system

UR - http://www.scopus.com/inward/record.url?scp=85035341027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035341027&partnerID=8YFLogxK

U2 - 10.1111/neup.12405

DO - 10.1111/neup.12405

M3 - Article

C2 - 28856744

AN - SCOPUS:85035341027

VL - 37

SP - 509

EP - 516

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 6

ER -